US 12,378,315 B2
Anti-rabbit CD19 antibodies and methods of use
Alexander Haas, Penzberg (DE); Friederike Jung, Penzberg (DE); Stefan Klostermann, Penzberg (DE); and Sonja Offner, Penzberg (DE)
Assigned to Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed by Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed on Jun. 29, 2021, as Appl. No. 17/362,126.
Application 17/362,126 is a continuation of application No. PCT/EP2019/087064, filed on Dec. 27, 2019.
Claims priority of application No. 18215920 (EP), filed on Dec. 30, 2018.
Prior Publication US 2022/0135672 A1, May 5, 2022
Int. Cl. C07K 16/28 (2006.01); C12N 5/0781 (2010.01)
CPC C07K 16/2803 (2013.01) [C12N 5/0635 (2013.01); C07K 2317/24 (2013.01); C12N 2500/80 (2013.01); C12N 2502/30 (2013.01)] 15 Claims
 
1. An antibody binding to rabbit CD19 comprising
(a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 32 or 33 or 34,
(b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 35 or 36,
(c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 37,
(d) a HVR-L1 comprising the amino acid sequence of SEQ ID NO: 38,
(e) a HVR-L2 comprising the amino acid sequence of SEQ ID NO: 39, and
(f) a HVR-L3 comprising the amino acid sequence of SEQ ID NO: 40.